226330 — Syntekabio Income Statement
0.000.00%
Last trade - 00:00- KR₩107bn
- KR₩117bn
- KR₩121m
Annual income statement for Syntekabio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 610 | 317 | 244 | 123 | 121 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7,707 | 9,183 | 12,031 | 13,075 | 14,552 |
| Operating Profit | -7,098 | -8,866 | -11,787 | -12,951 | -14,431 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6,488 | -14,803 | -4,506 | -11,398 | -7,213 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6,488 | -14,803 | -4,506 | -11,398 | -7,213 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6,488 | -14,803 | -4,506 | -11,398 | -7,213 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6,488 | -14,803 | -4,506 | -11,398 | -7,213 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -410 | -922 | -279 | -627 | -330 |
| Dividends per Share |